Brief: Bone Therapeutics: Sufficient Cash To Carry Out Business Objectives Until End Q4 2021

Biosenic SA

20/01/2021 06:17

Jan 20 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * PROVIDES Q4 2020 BUSINESS UPDATE AND 2021
    * ANTICIPATES REPORTING ON TOPLINE RESULTS FOR 3-MONTH
PRIMARY
ENDPOINT AND 6-MONTH FOLLOW-UP PERIOD IN Q3 OF 2021 FOR ITS
PIVOTAL PHASE III CLINICAL STUDY WITH IMPROVED VISCOSUPPLEMENT,
JTA-004
    * CLINICAL PROGRAMS RUNNING ON SCHEDULE, INCLUDING PHASE III
TRIAL
OF JTA-004 AND PHASE IIB TRIAL OF ALLOB
    * STRONG FINANCIAL POSITION FOLLOWING FUNDRAISING, LICENCING
AGREEMENT AND OPTIMISATION OF MANUFACTURING ASSETS
    * NET CASH UTILIZATION OF EUR 16.4 MILLION FOR FULL YEAR
2020 IS
IN LINE WITH COMPANY'S GUIDANCE OF EUR 15-16 MILLION
    * NET CASH POSITION TOTALED EUR 14.7 MILLION FOR YEAR ENDED
DECEMBER 31, 2020
    * OUTLOOK 2021: PLANS TO CONTINUE TO EXPAND ITS ALLOGENEIC
DIFFERENTIATED MSC BASED CELL THERAPY PLATFORM, BEYOND ALLOB,
INTO OTHER THERAPEUTIC INDICATIONS
    * COMPANY ANTICIPATES HAVING SUFFICIENT CASH TO CARRY OUT
ITS
BUSINESS OBJECTIVES UNTIL END Q4 2021
    * OUTLOOK 2021: CONTINUES TO HOLD DISCUSSIONS WITH POTENTIAL
PARTNERS TO EXPLORE BUSINESS OPPORTUNITIES AS JTA-004 IS
APPROACHING ANNOUNCEMENT OF PIVOTAL PHASE III TOPLINE RESULTS
    * OVER THE COURSE OF H1 2021, BONE THERAPEUTICS PLANS TO
CONTINUE
DISCUSSIONS WITH THE US FDA (FOOD AND DRUG ADMINISTRATION) IN
PREPARATION FOR THE NEXT STEPS IN THE CLINICAL DEVELOPMENT OF
JTA-004 AND ALLOB IN THE US

Source text for Eikon:  ID:nGNE8B3nQT 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))